Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:01 PM
Ignite Modification Date:
2025-12-24 @ 5:01 PM
NCT ID:
NCT07089550
Eligibility Criteria:
Inclusion Criteria:
* Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma);
* Patients undergoing PSMA PET for pre-treatment disease staging;
* Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA;
* Provision of signed informed consent for study participation and data handling.
Exclusion Criteria:
* Inability to remain supine and still for the PET/CT image acquisition;
* Prostate cancer with a known significant neuroendocrine component;
* Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer.
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT07089550
Study Brief:
Protocol Section:
NCT07089550